Kilitch Drugs (India) Limited

Informe acción NSEI:KILITCH

Capitalización de mercado: ₹5.0b

Kilitch Drugs (India) Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Kilitch Drugs (India) ha aumentado sus beneficios a una tasa media anual de 46.6%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 13.4% anual. Los ingresos han ido creciendo a una tasa media de 24.3% al año. La rentabilidad financiera de Kilitch Drugs (India) es de 7.5%, y sus márgenes netos son de 10.4%.

Información clave

46.6%

Tasa de crecimiento de los beneficios

46.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 17.5%
Tasa de crecimiento de los ingresos24.3%
Rentabilidad financiera7.5%
Margen neto10.4%
Última actualización de beneficios30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Jul 23
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Mar 05
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly

Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

Feb 02
Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump

We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Jan 30
We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease

Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Nov 17
Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings

Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

Sep 23
Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Sep 08
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

May 05
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors

Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Jul 06
Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt

Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

Apr 08
Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today

These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Dec 17
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well

Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Mar 21
Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 13
Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Dec 03
Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?

Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Aug 20
Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?

Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jul 16
Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Kilitch Drugs (India). Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NSEI:KILITCH Ingresos, gastos y beneficios (INR Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 241,5751652810
30 Jun 241,5131262520
31 Mar 241,5441462400
31 Dec 231,5501462430
30 Sep 231,5321402400
30 Jun 231,4271172380
31 Mar 231,3961042320
31 Dec 221,307981780
30 Sep 221,352851540
30 Jun 221,281831330
31 Mar 221,142741170
31 Dec 21976521320
30 Sep 21835631260
30 Jun 21780621100
31 Mar 2168537970
31 Dec 2060217890
30 Sep 205584910
30 Jun 20531-3920
31 Mar 2053381140
31 Dec 19609261030
30 Sep 19534-321110
30 Jun 19648-31270
31 Mar 19825381590
31 Mar 1851052770
31 Mar 17287-891720
31 Mar 16210-1121550
31 Mar 15190-31290
31 Dec 14222-8940
30 Sep 141998970
30 Jun 14168-1930
31 Mar 1414912870
31 Dec 1315135510

Ingresos de calidad: KILITCH tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (10.4%) de KILITCH son superiores a los del año pasado (9.2%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: KILITCH ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 46.6% al año.

Acelerando crecimiento: El crecimiento de los beneficios de KILITCH en el último año (17.3%) está por debajo de su media de 5 años (46.6% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de KILITCH en el último año (17.3%) no superó al de la industria Pharmaceuticals 20.5%.


Rentabilidad financiera

Alta ROE: La rentabilidad financiera de KILITCH (7.5%) se considera baja.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado